BCDIPLOMA
9.3.2022 23:12:12 CET | Business Wire | Press release
How can organisations protect against fraudulent certifications or fake English assessment test results? How can test takers in Europe receive their TOEIC ® test results in one click? How can test takers in Europe be sure that their test results are certified, tamper-proof and secure? To answer these questions, ETS Global, a subsidiary of ETS, chose to collaborate with BCdiploma, the industry-leading company for the digitisation of academic documents via blockchain technology. In Europe, ETS Global and BCdiploma are working on securing hundreds of thousands of digital TOEIC score reports via blockchain. For ETS Global, this is another step in its digital transformation. Starting from January 2022, TOEIC digital score reports are available in France and will be available across Europe during 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220223005682/en/
The result of this collaboration between these two leading players is a digital TOEIC score report that is :
- Secure: the storage of data on the blockchain makes it impossible to falsify the score report. BCdiploma complies with the strictest data protection regulations. In addition to the blockchain's encryption, BCdiploma adds its own secure, patented algorithms. This way, ETS Global and test takers retain full control over their data, which search engines cannot find or list.
- Universal: BCdiploma adapts to all consultation or sharing standards such as Verifiable Credentials from W3C and EBSI, Open Badges, EDCI, and more.
- User-friendly: available online in one click, this digitised document can be downloaded and sent by email, printed or exported in PDF format. A QR code is added to the document, which the test taker or the recipient of the certification can scan.
- Faster : because results are sent by email, test taker receive their scores faster compared to paper score report shipped by post.
- Streamlined: this digitalisation saves time for universities, schools and training organisations. The sending of results to test takers is automated. As for recruiters, they have access to a certified certificate, avoiding the need for inefficient "fact checking" to verify the authenticity of the document.
- More innovative : for the test taker, sending a secure link or a QR code of a certification guarantees quality and presents a modern picture to recruiters.
- More "carbon compatible"*: TOEIC digital score reports are issued using "Avalanche®", the latest generation and one of the most energy-efficient blockchains. Besides, stopping printing score reports will enable ETS Global to save seven trees/year. And without any paper score report to ship to test takers, ETS Global's carbon footprint will decrease by about 490kg of CO2 /year.
Miguel Membrado, Chief Digital Officer of ETS Global says: "The digitalisation of the education sector has been accelerating for years, and even more so since the start of the pandemic. Being able to offer digital TOEIC® test score reports to all ETS Global stakeholders is an obvious choice. We are delighted to be working with BCdiploma, a leading player in this field. As of today, we are offering this service to our test takers in Europe at no additional cost with the goal that within six months, the use of paper score reports in Europe will decline in favour of digital. This is not a war between digital and paper. Our customers will have the choice, of course. But we are convinced of the benefits of digitalisation to the overall customer experience, which this project perfectly illustrates."
Luc Jarry-Lacombe, CEO of BCdiploma, adds: "Our job as a software publisher is to reinvent a diploma that fits into the Digital Workplace. Better yet, it's about bringing the benefits of the blockchain system to test takers, recruiters, and all training organisations and institutions. 50% to 60% of our costs are dedicated to R&D, which enables us to deliver an impeccable service with the latest blockchain technologies. We are very happy to collaborate with the ETS Global teams, to offer more than a diploma: a real quality marketing object."
*already available in France. Deployment in Europe in 2022
About BCdiploma
BCdiploma has been trusted by more than 120 institutions, universities, and businesses in 18 countries. Our patented technology takes advantage of the latest blockchain and distributed storage technologies to deliver a high value Digital Credentials service. Our team brings to institutions a recognised expertise to succeed in their digital transformation projects. https://www.bcdiploma.com/en
About ETS Global
ETS Global B.V., a wholly owned subsidiary of ETS, is the international arm of ETS. At ETS Global B.V., we bring expertise to educational and business communities around the world, including companies, language schools, academic institutions and public service organisations. ETS Global serves 80 countries and offers a range of ETS products, services and learning solutions. https://www.etsglobal.org/fr/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005682/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom